Artiva Biotherapeutics, Inc. ARTV Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax at other companies
Other financials
Where this comes from
Reported directly by Artiva Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax.
The official record: Artiva Biotherapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Artiva Biotherapeutics, Inc.'s debt securities, available-for-sale, accumulated gross unrealized loss, before tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Artiva Biotherapeutics, Inc.'s debt securities, available-for-sale, accumulated gross unrealized loss, before tax?
- Artiva Biotherapeutics, Inc. (ARTV) reported debt securities, available-for-sale, accumulated gross unrealized loss, before tax of $44K in Q1 2026.
- How has Artiva Biotherapeutics, Inc.'s debt securities, available-for-sale, accumulated gross unrealized loss, before tax changed year-over-year?
- Artiva Biotherapeutics, Inc.'s debt securities, available-for-sale, accumulated gross unrealized loss, before tax decreased by 29.0% year-over-year, from $62K to $44K.
- What is the long-term trend for Artiva Biotherapeutics, Inc.'s debt securities, available-for-sale, accumulated gross unrealized loss, before tax?
- Over 2 years (2023 to 2025), Artiva Biotherapeutics, Inc.'s debt securities, available-for-sale, accumulated gross unrealized loss, before tax has grown at a -87.3% compound annual growth rate (CAGR), from $308K to $5K.